Characterization of an in vitro cell culture bioreactor system to evaluate anti-neoplastic drug regimens

Breast Cancer Research and Treatment

Volumn 96, Issue 3, 2006, Pages 217-225

  Kirstein, Mark N ^a   Brundage, Richard C ^a   Elmquist, William F ^a   Remmel, Rory P ^a   Marker, Paul H ^b   Guire, Dan E ^a   Yee, Douglas ^c  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Bioreactor; Gemcitabine; In vitro; MDA 231 cells; Pharmacokinetics; S phase

Indexed keywords

ANTINEOPLASTIC AGENT; GEMCITABINE;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BIOREACTOR; BREAST ADENOCARCINOMA; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE S PHASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DIFFUSION; DRUG EXPOSURE; DRUG INFUSION; EVALUATION; FLOW CYTOMETRY; FLOW RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PUMP; SIMULATION;

ANTIMETABOLITES, ANTINEOPLASTIC; AREA UNDER CURVE; BIOREACTORS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; DEOXYCYTIDINE; FEMALE; FLOW CYTOMETRY; HUMANS; LACTIC ACID;

EID: 33645748347     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-9004-z     Document Type: Article

References (41)

1. Tubergen DG, Stewart CF, Pratt CB, Zamboni WC, Winick N, Santana VM, Dryer ZA, Kurtzberg J, Bell B, Grier H, Vietti TJ: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a pediatric oncology group study. J Pediatr Hematol Oncol 18: 352-361, 1996
2. Stewart CF, Iacono LC, Chintagumpala M, Kellie SJ, Ashley D, Zamboni WC, Kirstein MN, Fouladi M, Seele LG, Wallace D, Houghton PJ, Gajjar A: Results of a phase II upfront window of pharmacokinetically guided topotecan in high-risk medulloblastoma and supratentorial primitive neuroectodermal tumor. J Clin Oncol 22: 3357-3365, 2004
3. Markman M, Rose PG, Jones E, Horowitz IR, Kennedy A, Webster K, Belinson J, Fusco N, Fluellen L, Kulp B, Peterson G, McGuire WP: Ninety-six-hour infusional paclitaxel as salvage therapy of ovarian cancer patients previously failing treatment with 3-hour or 24-hour paclitaxel infusion regimens. J Clin Oncol 16: 1849-1851, 1998
4. Brenner B, Ilson DH, Minsky BD, Bains MS, Tong W, Gonen M, Kelsen DP: Phase I trial of combined-modality therapy for localized esophageal cancer: escalating doses of continuous-infusion paclitaxel with cisplatin and concurrent radiation therapy. J Clin Oncol 22: 45-52, 2004
5. de Gramont A, Bosset JF, Milan C, Rougier P, Bouche O, Etienne PL, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L: Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 15: 808-815, 1997
6. Kellie SJ, Koopmans P, Earl J, Nath C, Roebuck D, Uges DR, De Graaf SS: Increasing the dosage of vincristine: a clinical and pharmacokinetic study of continuous-infusion vincristine in children with central nervous system tumors. Cancer 100: 2637-2643, 2004
7. Clark PI, Slevin ML, Joel SP, Osborne RJ, Talbot DI, Johnson PW, Reznek R, Masud T, Gregory W, Wrigley PF: A randomized trial of two etoposide schedules in small-cell lung cancer: the influence of pharmacokinetics on efficacy and toxicity. J Clin Oncol 12: 1427-1435, 1994
8. Suggitt M, Bibby MC: 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res 11: 971-981, 2005
9. Chou TC, Motzer RJ, Tong Y, Bosl GJ: Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. J Natl Cancer Inst 86: 1517-1524, 1994
10. Chou TC, Talalay P: Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22: 27-55, 1984
11. Suggitt M, Swaine DJ, Pettit GR, Bibby MC: Characterization of the hollow fiber assay for the determination of microtubule disruption in vivo. Clin Cancer Res 10: 6677-6685, 2004
12. Kirstein MN, Houghton PJ, Cheshire PJ, Richmond LB, Smith AK, Hanna SK, Stewart CF: Relation between 9-aminocamptothecin systemic exposure and tumor response in human solid tumor xenografts. Clin Cancer Res 7: 358-366, 2001
13. Stanness KA, Westrum LE, Fornaciari E, Mascagni P, Nelson JA, Stenglein SG, Myers T, Janigro D: Morphological and functional characterization of an in vitro blood-brain barrier model. Brain Res 771: 329-342, 1997
14. Drusano GL, Bilello PA, Symonds WT, Stein DS, McDowell J, Bye A, Bilello JA: Pharmacodynamics of abacavir in an in vitro hollow-fiber model system. Antimicrob Agents Chemother 46: 464-470, 2002
15. Bilello JA, Bauer G, Dudley MN, Cole GA, Drusano GL: Effect of 2′,3′-didehydro-3′-deoxythymidine in an in vitro hollow-fiber pharmacodynamic model system correlates with results of dose-ranging clinical studies. Antimicrob Agents Chemother 38: 1386-1391, 1994
16. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC: Phosphorylation of pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-nucleoside analog diphosphates by 3-phosphoglycerate kinase. J Biol Chem 277: 5453-5459, 2002
17. Bouffard DY, Laliberte J, Momparler RL: Kinetic studies on 2′,2′-difluorodeoxycytidine (Gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45: 1857-1861, 1993
18. Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC: Characterization of human UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue monophosphates. Cancer Res 62: 1624-1631, 2002
19. Heinemann V, Xu YZ, Chubb S, Sen A, Hertel LW, Grindey GB, Plunkett W: Inhibition of ribonucleotide reduction in CCRF-CEM cells by 2′,2′- difluorodeoxycytidine. Mol Pharmacol 38: 567-572, 1990
20. Ross Cuddy DD. DP: Molecular effects of 2′,2′- difluorodeoxycytidine (Gemcitabine) on DNA replication in intact HL-60 cells. Biochem Pharmacol 48: 1619-1630, 1994
21. Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W: Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51: 6110-6117, 1991
22. Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, : A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9: 491-498, 1991
23. Venook AP, Egorin MJ, Rosner GL, Hollis D, Mani S, Hawkins M, Byrd J, Hohl R, Budman D, Meropol NJ, Ratain MJ: Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: cancer and Leukemia Group B 9565. J Clin Oncol 18: 2780-2787, 2000
24. Dumez H, Louwerens M, Pawinsky A, Planting AS, de Jonge MJ, Van Oosterom AT, Highley M, Guetens G, Mantel M, de Boeck G, de Bruijn E, Verweij J: The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors. Anticancer Drugs 13: 583-593, 2002
25. Kroep JR, Giaccone G, Voorn DA, Smit EF, Beijnen JH, Rosing H, van Moorsel CJ, van Groeningen CJ, Postmus PE, Pinedo HM, Peters GJ: Gemcitabine and paclitaxel: pharmacokinetic and pharmacodynamic interactions in patients with non-small-cell lung cancer. J Clin Oncol 17: 2190-2197, 1999
26. Tempero M, Plunkett W, Van Ruiz Haperen V, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J: Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21: 3402-3408, 2003
27. D'Argenio DZ, AADAPT II User's Guide: Pharmacokinetic/Pharmacodynamic Systems Analysis Software. Biomedical Simulations Resource Los Angeles, 1997
28. Gibaldi M, Koup JR: Pharmacokinetic concepts - drug binding, apparent volume of distribution and clearance. Eur J Clin Pharmacol 20: 299-305, 1981
29. Gooch JL, Van Den Berg CL, Yee D: Insulin-like growth factor (IGF)-I rescues breast cancer cells from chemotherapy-induced cell death-proliferative and anti-apoptotic effects. Breast Cancer Res Treat 56: 1-10, 1999
30. Marbach Weil EP. MH: Rapid enzymatic measurement of blood lactate and pyruvate. Use and significance of metaphosphoric acid as a common precipitant. Clin Chem 13: 314-325, 1967
31. Company EL, Package Insert
32. Rew DA, Wilson GD: Cell production rates in human tissues and tumours and their significance. Part II: clinical data. Eur J Surg Oncol 26: 405-417, 2000
33. Yamamoto D, Tanaka K, Nakai K, Baden T, Inoue K, Yamamoto C, Takemoto H, Kamato K, Hirata H, Morikawa S, Inubushi T, Hioki K: Synergistic effects induced by cycloprodigiosin hydrochloride and epirubicin on human breast cancer cells. Breast Cancer Res Treat 72: 1-10, 2002
34. Tolis C, Peters GJ, Ferreira CG, Pinedo HM, Giaccone G: Cell cycle disturbances and apoptosis induced by topotecan and gemcitabine on human lung cancer cell lines. Eur J Cancer 35: 796-807, 1999
35. Cappella P, Tomasoni D, Faretta M, Lupi M, Montalenti F, Viale F, Banzato F, D'Incalci M, Ubezio P: Cell cycle effects of gemcitabine. Int J Cancer 93: 401-408, 2001
36. Ng SSW, Tsao MS, Chow S, Hedley DW: Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res 60: 5451-5455, 2000
37. Pauwels B, Korst AE, Pattyn GG, Lambrechts HA, Van Bockstaele DR, Vermeulen K, Lenjou M, de Pooter CM, Vermorken JB, Lardon F: Cell cycle effect of gemcitabine and its role in the radiosensitizing mechanism in vitro. Int J Radiat Oncol Biol Phys 57: 1075-1083, 2003
38. Perabo FG, Lindner H, Schmidt D, Huebner D, Blatter J, Fimmers R, Muller SC, Albers P: Preclinical evaluation of gemcitabine/paclitaxel-interactions in human bladder cancer lines. Anticancer Res 23: 4805-4814, 2003
39. Ali S, El-Rayes BF, Aranha O, Sarkar FH, Philip PA: Sequence dependent potentiation of gemcitabine by flavopiridol in human breast cancer cells. Breast Cancer Res Treat 90: 25-31, 2005
40. Chandler NM, Canete JJ, Callery MP: Caspase-3 drives apoptosis in pancreatic cancer cells after treatment with gemcitabine. J Gastrointest Surg 8: 1072-1078, 2004
41. Serrano MJ, Sanchez-Rovira P, Algarra I, Jaen A, Lozano A, Gaforio JJ: Evaluation of a gemcitabine-doxorubicin-paclitaxel combination schedule through flow cytometry assessment of apoptosis extent induced in human breast cancer cell lines. Jpn J Cancer Res 93: 559-566, 2002